CD8A and neoplasm: Similarly, in the CT2A tumor model, ZIKV treatment elicited an increase in numbers of CD45+ leukocytes (~4-fold), including CD4+ T cells (~7.5-fold), CD8+ T cells (~8.9-fold), NK cells (~2-fold), NKT cells (~2-fold), and Trm cells (~8-fold), compared with control-treated mice (Figure 2B).